Tezspire (tezepelumab)

pCPA File Number: 22089
Negotiation Status:
Concluded with an LOI
Indication(s):
Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CDA-AMC Project Number:
SR0731-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: